claim: safety and immunogenicity study of p-ncov vaccine to prevent sars-cov-2 infection
evidence_1: this clinical trial is designed to assess the safety, reactogenicity and immunogenicity of mrna-1273 manufactured by modernatx, inc. mrna-1273 is a novel lipid nanoparticle (lnp)-encapsulated mrna-based vaccine that encodes for a full-length, prefusion stabilized spike (s) protein of sars-cov-2.", "we aimed to assess the safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 (sars-cov-2) vaccine candidate, bbibp-corv, in humans.")